首页> 外文期刊>Bone marrow transplantation >Eradication of residual bcr-abl-positive clones by inducing graft-versus-host disease after allogeneic stem cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
【24h】

Eradication of residual bcr-abl-positive clones by inducing graft-versus-host disease after allogeneic stem cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

机译:在费城染色体阳性的急性淋巴细胞白血病患者中,通过异体干细胞移植后诱导移植物抗宿主病,消除了残留的bcr-abl阳性克隆。

获取原文
获取原文并翻译 | 示例
       

摘要

Persistence of bcr-abl transcripts after marrow grafting is thought to convey a high risk for relapse in patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL). Donor leukocyte infusion (DLI) is closely associated with development of graft-versus-host disease (GVHD) and has well-defined activity against relapsed chronic myelogenous leukemia (CML) but not ALL. We report two patients with Ph-positive ALL who remained bcr-abl positive by reverse transcriptase polymerase chain reaction (RT-PCR) after marrow grafting. Residual bcr-abl transcripts in both patients were eliminated following acute GVHD, which was induced by either DLI or rapid reduction of immunosuppression. Both patients have continued in complete molecular remission for 18 months and 8 months following transplantation, respectively. Our observation suggests that induction of GVHD may eliminate minimal residual disease, thereby preventing leukemia relapse in patients transplanted for Ph-positive ALL.
机译:bcr-abl转录物在骨髓移植后的持续存在被认为在费城染色体(Ph)阳性的急性淋巴细胞白血病(ALL)患者中复发的风险很高。供体白细胞输注(DLI)与移植物抗宿主病(GVHD)的发展密切相关,并且对复发性慢性粒细胞性白血病(CML)具有明确的活性,但对ALL却没有。我们报道了两名Ph阳性的患者,它们在骨髓移植后通过逆转录聚合酶链反应(RT-PCR)保持bcr-abl阳性。急性GVHD后,这两名患者的残留bcr-abl转录物均被清除,这是由DLI或免疫抑制的快速降低引起的。两名患者分别在移植后分别持续了18个月和8个月的完全分子缓解。我们的观察结果表明,GVHD的诱导可以消除残留的疾病,从而预防Ph阳性ALL移植患者的白血病复发。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号